CA2132836C - Immunization by inoculation of dna transcription unit - Google Patents
Immunization by inoculation of dna transcription unit Download PDFInfo
- Publication number
- CA2132836C CA2132836C CA002132836A CA2132836A CA2132836C CA 2132836 C CA2132836 C CA 2132836C CA 002132836 A CA002132836 A CA 002132836A CA 2132836 A CA2132836 A CA 2132836A CA 2132836 C CA2132836 C CA 2132836C
- Authority
- CA
- Canada
- Prior art keywords
- influenza virus
- vertebrate
- polynucleotide sequence
- dna
- immunization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003053 immunization Effects 0.000 title claims abstract description 37
- 238000002649 immunization Methods 0.000 title claims abstract description 33
- 238000013518 transcription Methods 0.000 title description 35
- 230000035897 transcription Effects 0.000 title description 35
- 238000011081 inoculation Methods 0.000 title description 27
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 35
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 32
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 32
- 239000002157 polynucleotide Substances 0.000 claims abstract description 32
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 24
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 24
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 24
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 24
- 239000013612 plasmid Substances 0.000 claims abstract description 20
- 230000028993 immune response Effects 0.000 claims abstract description 18
- 230000001580 bacterial effect Effects 0.000 claims abstract description 16
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 55
- 230000001681 protective effect Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 241000271566 Aves Species 0.000 abstract description 30
- 239000000185 hemagglutinin Substances 0.000 abstract description 15
- 230000001717 pathogenic effect Effects 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000028996 humoral immune response Effects 0.000 abstract description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract description 3
- 230000006023 anti-tumor response Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 83
- 238000002474 experimental method Methods 0.000 description 35
- 241000287828 Gallus gallus Species 0.000 description 23
- 235000013330 chicken meat Nutrition 0.000 description 23
- 241000700605 Viruses Species 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 13
- 231100000518 lethal Toxicity 0.000 description 12
- 230000001665 lethal effect Effects 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 10
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 9
- 229960003805 amantadine Drugs 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 239000012678 infectious agent Substances 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 244000052769 pathogen Species 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000713826 Avian leukosis virus Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108010020194 Influenza Virus Hemagglutinin Glycoproteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940124395 anti-influenza a virus drug Drugs 0.000 description 1
- 229940124393 anti-influenza virus drug Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 208000012331 ruffled feather Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11041—Use of virus, viral particle or viral elements as a vector
- C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Abstract
This invention relates to a polynucleotide sequence consisting essentially of a DNA encoding a desired antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for use in vertebrate immunization. The uptake of the polynucleotide sequence by a host vertebrate results in the expression of the desired antigen or antigens, for example hemagglutinin, thereby eliciting humoral or cell-mediated immune responses or both.
The elicited immune response can provide protection against infection by pathogenic agents, provide an anti-tumor response, or provide contraception. The host can be any vertebrate, avian or mammal, including humans.
The elicited immune response can provide protection against infection by pathogenic agents, provide an anti-tumor response, or provide contraception. The host can be any vertebrate, avian or mammal, including humans.
Description
IbMUNIZATION BY INOCULATION OF DNA TRANSCRIPTION UNIT
Background of the Invention Vaccination with inactivated or attenuated organisms or their products has been shown to be an effective method for increasing host resistance and ultimately has led to the eradication of certain common and serious infectious diseases. The use of vaccines is based on the stimulation of specific immune response within a host or the transfer of preformed antibodies. The prevention of certain diseases, such as poliomyelitis, by vaccines represents one of immunology's greatest triumphs.
Effective vaccines have been developed for relatively few of the infectious agents that cause disease in domestic animals and man. This reflects technical problems associated with the growth and attenuation of virulent strains of pathogens. Recently effort has been placed on the development of subunit vaccines (vaccines that present only selected antigens from a pathogen to the host). Subunit vaccines have the potential for achieving high levels of protection in the virtual absence of side effects. Subunit vaccines also offer the opportunity for the development of vaccines that are stable, easy to administer, and sufficiently cost-effective for widespread distribution.
Summary of the Invention This invention relates to a product for use in vertebrate immunization, comprising a polynucleotide sequence consisting essentially of a DNA encoding a desired antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences. The uptake of the DNA
transcription unit by host cells results in the expression of the desired antigen or antigens, thereby eliciting humoral or cell-mediated immune responses or both humoral and cell-mediated responses. The elicited humoral and cell-mediated immune response can provide protection against infection by pathogenic agents, provide an anti-tumor response, or provide contraception. The host can be any vertebrate, avian or mammal, including humans.
In one aspect, the invention also relates to the use of a polynucleotide sequence consisting essentially of a DNA
encoding a desired antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for use in vertebrate immunization. It also relates to the use of the polynucleotide sequence in the manufacture of a medicament for use in vertebrate immuni zation .
In one aspect, the medicament is free of a viral vector.
The invention further relates to the use of the polynucleotide sequence in a form amenable to mucosal surface administration.
In one aspect, the polynucleotide sequence is replication deficient.
In a further aspect, the invention provides a product for use in vertebrate immunization, comprising a virus replication defective polynucleotide sequence consisting essentially of a DNA encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence expresses the influenza virus antigen in the vertebrate, thereby eliciting an immune response in the vertebrate.
In another aspect, the invention provides a product for use in vertebrate immunization, comprising a virus replication defective polynucleotide sequence consisting of a DNA encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence expresses the influenza virus antigen in the vertebrate, thereby eliciting an immune response in the vertebrate.
In a still further aspect, the invention provides a product for use in vertebrate immunization, comprising a virus -2a-replication defective polynucleotide sequence comprising a DNA
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence is free of a viral particle, and wherein the polynucleotide sequence expresses the influenza virus antigen in the vertebrate, thereby eliciting an immune response in the vertebrate.
In accordance with certain aspects of the present invention, the influenza virus antigen is an influenza virus hemagglutinin protein. Expression of the polynucleotide sequence elicites a protective immune response against the influenza virus in a vertebrate.
The DNA transcription unit introduced by the present invention can be used to express any antigen encoded by an infectious agent, such as a virus, a bacterium, a fungus, or a parasite, as well as antigenic fragments and peptides that have been experimentally determined to be effective in immunizing an individual against infection by a pathogenic agent. As stated above, DNA transcription units can also be used for contraceptive purposes or for anti-cancer therapy.
The desired antigen to be expressed can be designed so as to give internal, surface, secreted, or budding and assembled forms of the antigens being used as immunogens.
There are numerous advantages for the use of DNA for immunizations. For example, immunization can be accomplished for any antigen encoded by DNA. Furthermore, the DNA encoded antigens are expressed as "pure" antigens in their native states and have undergone normal host cell modifications.
Also, DNA is easily and inexpensively manipulated and is stable as a dry product or in solution over a wide range of temperatures. Thus, this technology is valuable for the development of highly effective subunit vaccines.
Background of the Invention Vaccination with inactivated or attenuated organisms or their products has been shown to be an effective method for increasing host resistance and ultimately has led to the eradication of certain common and serious infectious diseases. The use of vaccines is based on the stimulation of specific immune response within a host or the transfer of preformed antibodies. The prevention of certain diseases, such as poliomyelitis, by vaccines represents one of immunology's greatest triumphs.
Effective vaccines have been developed for relatively few of the infectious agents that cause disease in domestic animals and man. This reflects technical problems associated with the growth and attenuation of virulent strains of pathogens. Recently effort has been placed on the development of subunit vaccines (vaccines that present only selected antigens from a pathogen to the host). Subunit vaccines have the potential for achieving high levels of protection in the virtual absence of side effects. Subunit vaccines also offer the opportunity for the development of vaccines that are stable, easy to administer, and sufficiently cost-effective for widespread distribution.
Summary of the Invention This invention relates to a product for use in vertebrate immunization, comprising a polynucleotide sequence consisting essentially of a DNA encoding a desired antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences. The uptake of the DNA
transcription unit by host cells results in the expression of the desired antigen or antigens, thereby eliciting humoral or cell-mediated immune responses or both humoral and cell-mediated responses. The elicited humoral and cell-mediated immune response can provide protection against infection by pathogenic agents, provide an anti-tumor response, or provide contraception. The host can be any vertebrate, avian or mammal, including humans.
In one aspect, the invention also relates to the use of a polynucleotide sequence consisting essentially of a DNA
encoding a desired antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for use in vertebrate immunization. It also relates to the use of the polynucleotide sequence in the manufacture of a medicament for use in vertebrate immuni zation .
In one aspect, the medicament is free of a viral vector.
The invention further relates to the use of the polynucleotide sequence in a form amenable to mucosal surface administration.
In one aspect, the polynucleotide sequence is replication deficient.
In a further aspect, the invention provides a product for use in vertebrate immunization, comprising a virus replication defective polynucleotide sequence consisting essentially of a DNA encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence expresses the influenza virus antigen in the vertebrate, thereby eliciting an immune response in the vertebrate.
In another aspect, the invention provides a product for use in vertebrate immunization, comprising a virus replication defective polynucleotide sequence consisting of a DNA encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence expresses the influenza virus antigen in the vertebrate, thereby eliciting an immune response in the vertebrate.
In a still further aspect, the invention provides a product for use in vertebrate immunization, comprising a virus -2a-replication defective polynucleotide sequence comprising a DNA
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence is free of a viral particle, and wherein the polynucleotide sequence expresses the influenza virus antigen in the vertebrate, thereby eliciting an immune response in the vertebrate.
In accordance with certain aspects of the present invention, the influenza virus antigen is an influenza virus hemagglutinin protein. Expression of the polynucleotide sequence elicites a protective immune response against the influenza virus in a vertebrate.
The DNA transcription unit introduced by the present invention can be used to express any antigen encoded by an infectious agent, such as a virus, a bacterium, a fungus, or a parasite, as well as antigenic fragments and peptides that have been experimentally determined to be effective in immunizing an individual against infection by a pathogenic agent. As stated above, DNA transcription units can also be used for contraceptive purposes or for anti-cancer therapy.
The desired antigen to be expressed can be designed so as to give internal, surface, secreted, or budding and assembled forms of the antigens being used as immunogens.
There are numerous advantages for the use of DNA for immunizations. For example, immunization can be accomplished for any antigen encoded by DNA. Furthermore, the DNA encoded antigens are expressed as "pure" antigens in their native states and have undergone normal host cell modifications.
Also, DNA is easily and inexpensively manipulated and is stable as a dry product or in solution over a wide range of temperatures. Thus, this technology is valuable for the development of highly effective subunit vaccines.
Brief Description of the Drawings Figure 1 is an illustration of a bacterial plasmid containing a DNA transcription unit (referred to as pPl/H7) comprising an influenza virus hemagglutinin type 7 (H7) gene expressed by a replication competent retroviral vector.
Figure 2 is an illustration of a bacterial plasmid containing a DNA transcription unit (p188) comprising an influenza virus hemagglutinin type 7 (H7) gene expressed by a replication defective retroviral vector.
Figure 3 is an illustration of a bacterial plasmid comprising a retroviral vector (pRCAS) with no H7 insert, used as a control.
Figure 4A is a schematic representation of the nonretroviral vector comprising the influenza virus antigen DNA transcription unit encoding subtype H7 hemagglutinin.
Figure 4B is a schematic representation of the nonretroviral vector comprising the influenza virus antigen DNA transcription unit encoding subtype H1 hemagglutinin.
Figure 4C is a schematic representation of the nonretroviral vector comprising a control DNA
transcription unit, encoding no influenza virus antigens.
Figure 5 is a bar graph depicting the maximum median weight loss for DNA-vaccinated mice in experiment 4, Table 7.
Detailed Description of the Invention This invention relates to use of a DNA transcription unit for immunizing vertebrates, particularly mammals, including humans, against a pathogen, or infectious agent, thereby eliciting humoral and/or cell-medicated immune responses which limit the spread or growth of the infectious agent and result in protection against subsequent challenge by the pathogen or infectious agent. .
The term "immunizing" refers herein to the production of an immune response in a vertebrate which protects (partially or totally) from the manifestations of infection (i.e., disease) caused by an infectious agent.
That is, a vertebrate immunized by the present invention will not be infected or will be infected to a lesser extent than would occur without immunization.
A DNA transcription unit is a polynucleotide sequence which includes at least two components: antigen-encoding DNA and transcriptional promoter elements. A DNA
transcription unit may optionally include additional sequences, such as: enhancer elements, splicing signals, termination and polyadenylation signals, viral replicons and bacterial plasmid sequences.
The DNA transcription unit can be produced by a number of known methods. For example, using known methods, DNA encoding the desired antigen can be inserted into an expression vector to construct the DNA
transcription unit. See Maniatis et al., Molecular Cloninq, A Laboratory Manual, 2d, Cold Spring Harbor Laboratory Press (1989).
The DNA transcription unit can be administered to an individual, or inoculated, in the presence of adjuvants or other substances that have the capability of promoting DNA
uptake or recruiting immune system cells to the site of the inoculation. It should be understood that the DNA
transcription unit itself will be expressed by host cell factors.
The "desired antigen" can be any antigen expressed by an infectious agent or any antigen that has been determined to be capable of eliciting a protective response against an infectious agent. These antigens may or may not be structural components of the infectious '-vO 93/19183 2 ~ ~ 2836 PCT/US93/02394 agent. The encoded antigens can be translation products or polypeptides. The polypeptides can be of various lengths. They can undergo normal host cell modifications such as glycosylation, myristoylation or phosphorylation.
In addition, they can be designed to undergo intra-cellular, extracellular or cell-surface expression.
Furthermore, they can be designed to undergo assembly and release from cells.
Potential pathogens for which the DNA transcription unit can be used include DNA encoding antigens derived from any virus, chlamydia, mycoplasma, bacteria, parasite or fungi. Viruses include the herpesviruses orthomyxoviruses, rhinoviruses, picornaviruses, adenoviruses, paramyxoviruses, coronaviruses, rhabdoviruses, togaviruses, flaviviruses, bunyaviruses, rubella virus, reovirus, hepadna viruses and retroviruses including human immunodeficiency virus. Bacteria include mycobacteria, spirochetes, rickettsias, chlamydia, and mycoplasma. Fungi include yeasts and molds. Parasites include malaria. It is to be understood that this list does not include all potential pathogens against which a protective immune response can be generated according to the methods herein described.
An individual can be inoculated through any parenteral route. For example, an individual can be inoculated by intranasal, intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular methods. In a particular embodiment of the present invention, an individual is vaccinated by contacting a mucosal surface on the individual with the desired DNA transcription unit in a physiologically compatible medium. The DNA
transcription unit can be administered to a mucosal surface by a variety of methods, including DNA-containing nose-drops, inhalants and suppositories.
WO 93/19183 2132836 PCT/US93/0239,' Any appropriate physiologically compatible medium, such as saline, is suitable.for introducing the DNA
transcription unit into an individual.
The following Examples describe vaccination trials using direct DNA inoculations designed for use in both avian and murine influenza virus models. Both of these models afford rapid assays for protective immunizations against lethal challenges, wherein challenge of an unimmunized animal causes death within 1-2 weeks.
Immunization as described herein has been accomplished with DNA transcription units (i.e., vectors) that express an influenza virus hemagglutinin glycoprotein. This protein mediates adsorption and penetration of virus and is a major target for neutralizing antibodies. Influenza virus hemagglutinin proteins have 14 different serological subtypes. In the avian model, DNA expression vectors for the H7 subtype (comprising a DNA transcription unit encoding the H7 subtype hemagglutinin) have been used to provide protection against challenge with an H7N7 virus. In the murine model, a DNA transcription unit expressing the H1 hemagglutinin was used to immunize against an H1N1 virus.
Example 1- Immunization of Chickens Against Influenza Virus Procedure:
A DNA transcription unit referred to as pPl/H7 (Fig.
1), encoding a replication competent avian leukosis virus expressing the influenza virus hemagglutinin type 7 (H7) gene was constructed as described in Hunt et al., J. of Virolocrv, 62(8):3014-3019 (1988). DNA unit p188 (Fig. 2) encoding a replication defective derivative of pPl/H7 that expresses H7 but is defective for the avian virus vector polymerase and envelope proteins was constructed by deleting an XbaI fragment from pPl/H7. DNA unit pRCAS
WO 93/19183 21" 2836 PCT/US93/02394 (Fig. 3), encoding the avian leukosis virus vector, with no influenza virus insert, was constructed as described in Hughes et al., J. of Virolocrv, 61:3004 (1987). DNA units were diluted in saline at a concentration of 100 g per 0.2 ml for inoculation.
To test the ability of the inoculated DNA to protect against a lethal influenza virus challenge, groups of three-week old chicks were inoculated with pPl/H7, p188, or pRCAS DNA. Specific pathogen free chicks that are maintained as an avian-leukosis virus-free flock (SPAFAS, Norwich, CT) were used for inoculations. Each chick received 100 g of DNA (-1x1013 molecules) intravenously (iv), 100 g intraperitoneally (ip), and 100 g subcutaneously (sc). Four weeks later chicks were bled and boosted with 300 g of DNA (100 g iv, 100 g ip, and 100 g sc). At one week post-boost, chicks were bled and challenged by the nares with 100 lethal doses (1x104 egg infectious doses) of a highly pathogenic type H7 avian influenza virus, A/Chicken/Victoria/1/85 (H7N7) (Ck/Vic/85). The chickens were observed daily for ten days for signs of disease. One and one half weeks after challenge, sera were obtained from surviving birds. These as well as the pre- and post-boost sera were used for analyses for hemagglutination inhibiting antibodies (HI).
Sera were analyzed in microtiter plates with receptor-destroying enzyme-treated sera as described by Palmer et al., Advanced Laboratory Techniques for Influenza Diagnosis, p. 51-52, Immunology series no. 6, U.S. Department of Health, Education, and Welfare, Washington, D.C. (1975).
Results:
The H7-expressing DNA transcription units protected each of the chickens inoculated with pPl/H7 or p188 (Table 1). In contrast, inoculation with the control DNA, pRCAS, WO 93/19183 21328'36 PCT/US93/0239' failed to protect the chickens against lethal virus challenge. The birds in the control group started to show signs of disease on the second day post-challenge. By the third day, three of the six control birds had died and all control birds were dead by the fifth day. The birds inoculated with hemagglutinin-expressing DNAs showed no signs of disease. By one and one half weeks post challenge both of these groups had developed high levels of HI antibody.
Example 2 - Immunization Against Influenza Virus is Reproducible To assess the reproducibility of the protection elicited by immunization with the replication-defective H7-expressing DNA, the experiment described in Example 1 was repeated three times using only p188 and pRCAS DNAs for inoculations. The results of the repeat experiments confirmed that the H7-expressing p188 DNA could afford protection against a lethal challenge (Table 2). In contrast to the first experiment, in which all of the p188-inoculated chickens survived the lethal challenge, immunizations in the 2nd, 3rd, and 4th experiments achieved only partial protection with from 28% to 83% of the vaccinated birds surviving. Further, in contrast to the first experiment in which vaccinated birds showed no signs of disease, most of the survivors of the repeat experiments showed transient signs of post-challenge sickness. As in the first experiment, the control DNA did not provide protection. Summing the results of the 4 experiments, 28 out of 56 p188-vaccinated birds survived whereas only 1 of 55 control DNA-inoculated birds survived. Thus, despite the variability, significant immunization was achieved.
Figure 2 is an illustration of a bacterial plasmid containing a DNA transcription unit (p188) comprising an influenza virus hemagglutinin type 7 (H7) gene expressed by a replication defective retroviral vector.
Figure 3 is an illustration of a bacterial plasmid comprising a retroviral vector (pRCAS) with no H7 insert, used as a control.
Figure 4A is a schematic representation of the nonretroviral vector comprising the influenza virus antigen DNA transcription unit encoding subtype H7 hemagglutinin.
Figure 4B is a schematic representation of the nonretroviral vector comprising the influenza virus antigen DNA transcription unit encoding subtype H1 hemagglutinin.
Figure 4C is a schematic representation of the nonretroviral vector comprising a control DNA
transcription unit, encoding no influenza virus antigens.
Figure 5 is a bar graph depicting the maximum median weight loss for DNA-vaccinated mice in experiment 4, Table 7.
Detailed Description of the Invention This invention relates to use of a DNA transcription unit for immunizing vertebrates, particularly mammals, including humans, against a pathogen, or infectious agent, thereby eliciting humoral and/or cell-medicated immune responses which limit the spread or growth of the infectious agent and result in protection against subsequent challenge by the pathogen or infectious agent. .
The term "immunizing" refers herein to the production of an immune response in a vertebrate which protects (partially or totally) from the manifestations of infection (i.e., disease) caused by an infectious agent.
That is, a vertebrate immunized by the present invention will not be infected or will be infected to a lesser extent than would occur without immunization.
A DNA transcription unit is a polynucleotide sequence which includes at least two components: antigen-encoding DNA and transcriptional promoter elements. A DNA
transcription unit may optionally include additional sequences, such as: enhancer elements, splicing signals, termination and polyadenylation signals, viral replicons and bacterial plasmid sequences.
The DNA transcription unit can be produced by a number of known methods. For example, using known methods, DNA encoding the desired antigen can be inserted into an expression vector to construct the DNA
transcription unit. See Maniatis et al., Molecular Cloninq, A Laboratory Manual, 2d, Cold Spring Harbor Laboratory Press (1989).
The DNA transcription unit can be administered to an individual, or inoculated, in the presence of adjuvants or other substances that have the capability of promoting DNA
uptake or recruiting immune system cells to the site of the inoculation. It should be understood that the DNA
transcription unit itself will be expressed by host cell factors.
The "desired antigen" can be any antigen expressed by an infectious agent or any antigen that has been determined to be capable of eliciting a protective response against an infectious agent. These antigens may or may not be structural components of the infectious '-vO 93/19183 2 ~ ~ 2836 PCT/US93/02394 agent. The encoded antigens can be translation products or polypeptides. The polypeptides can be of various lengths. They can undergo normal host cell modifications such as glycosylation, myristoylation or phosphorylation.
In addition, they can be designed to undergo intra-cellular, extracellular or cell-surface expression.
Furthermore, they can be designed to undergo assembly and release from cells.
Potential pathogens for which the DNA transcription unit can be used include DNA encoding antigens derived from any virus, chlamydia, mycoplasma, bacteria, parasite or fungi. Viruses include the herpesviruses orthomyxoviruses, rhinoviruses, picornaviruses, adenoviruses, paramyxoviruses, coronaviruses, rhabdoviruses, togaviruses, flaviviruses, bunyaviruses, rubella virus, reovirus, hepadna viruses and retroviruses including human immunodeficiency virus. Bacteria include mycobacteria, spirochetes, rickettsias, chlamydia, and mycoplasma. Fungi include yeasts and molds. Parasites include malaria. It is to be understood that this list does not include all potential pathogens against which a protective immune response can be generated according to the methods herein described.
An individual can be inoculated through any parenteral route. For example, an individual can be inoculated by intranasal, intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular methods. In a particular embodiment of the present invention, an individual is vaccinated by contacting a mucosal surface on the individual with the desired DNA transcription unit in a physiologically compatible medium. The DNA
transcription unit can be administered to a mucosal surface by a variety of methods, including DNA-containing nose-drops, inhalants and suppositories.
WO 93/19183 2132836 PCT/US93/0239,' Any appropriate physiologically compatible medium, such as saline, is suitable.for introducing the DNA
transcription unit into an individual.
The following Examples describe vaccination trials using direct DNA inoculations designed for use in both avian and murine influenza virus models. Both of these models afford rapid assays for protective immunizations against lethal challenges, wherein challenge of an unimmunized animal causes death within 1-2 weeks.
Immunization as described herein has been accomplished with DNA transcription units (i.e., vectors) that express an influenza virus hemagglutinin glycoprotein. This protein mediates adsorption and penetration of virus and is a major target for neutralizing antibodies. Influenza virus hemagglutinin proteins have 14 different serological subtypes. In the avian model, DNA expression vectors for the H7 subtype (comprising a DNA transcription unit encoding the H7 subtype hemagglutinin) have been used to provide protection against challenge with an H7N7 virus. In the murine model, a DNA transcription unit expressing the H1 hemagglutinin was used to immunize against an H1N1 virus.
Example 1- Immunization of Chickens Against Influenza Virus Procedure:
A DNA transcription unit referred to as pPl/H7 (Fig.
1), encoding a replication competent avian leukosis virus expressing the influenza virus hemagglutinin type 7 (H7) gene was constructed as described in Hunt et al., J. of Virolocrv, 62(8):3014-3019 (1988). DNA unit p188 (Fig. 2) encoding a replication defective derivative of pPl/H7 that expresses H7 but is defective for the avian virus vector polymerase and envelope proteins was constructed by deleting an XbaI fragment from pPl/H7. DNA unit pRCAS
WO 93/19183 21" 2836 PCT/US93/02394 (Fig. 3), encoding the avian leukosis virus vector, with no influenza virus insert, was constructed as described in Hughes et al., J. of Virolocrv, 61:3004 (1987). DNA units were diluted in saline at a concentration of 100 g per 0.2 ml for inoculation.
To test the ability of the inoculated DNA to protect against a lethal influenza virus challenge, groups of three-week old chicks were inoculated with pPl/H7, p188, or pRCAS DNA. Specific pathogen free chicks that are maintained as an avian-leukosis virus-free flock (SPAFAS, Norwich, CT) were used for inoculations. Each chick received 100 g of DNA (-1x1013 molecules) intravenously (iv), 100 g intraperitoneally (ip), and 100 g subcutaneously (sc). Four weeks later chicks were bled and boosted with 300 g of DNA (100 g iv, 100 g ip, and 100 g sc). At one week post-boost, chicks were bled and challenged by the nares with 100 lethal doses (1x104 egg infectious doses) of a highly pathogenic type H7 avian influenza virus, A/Chicken/Victoria/1/85 (H7N7) (Ck/Vic/85). The chickens were observed daily for ten days for signs of disease. One and one half weeks after challenge, sera were obtained from surviving birds. These as well as the pre- and post-boost sera were used for analyses for hemagglutination inhibiting antibodies (HI).
Sera were analyzed in microtiter plates with receptor-destroying enzyme-treated sera as described by Palmer et al., Advanced Laboratory Techniques for Influenza Diagnosis, p. 51-52, Immunology series no. 6, U.S. Department of Health, Education, and Welfare, Washington, D.C. (1975).
Results:
The H7-expressing DNA transcription units protected each of the chickens inoculated with pPl/H7 or p188 (Table 1). In contrast, inoculation with the control DNA, pRCAS, WO 93/19183 21328'36 PCT/US93/0239' failed to protect the chickens against lethal virus challenge. The birds in the control group started to show signs of disease on the second day post-challenge. By the third day, three of the six control birds had died and all control birds were dead by the fifth day. The birds inoculated with hemagglutinin-expressing DNAs showed no signs of disease. By one and one half weeks post challenge both of these groups had developed high levels of HI antibody.
Example 2 - Immunization Against Influenza Virus is Reproducible To assess the reproducibility of the protection elicited by immunization with the replication-defective H7-expressing DNA, the experiment described in Example 1 was repeated three times using only p188 and pRCAS DNAs for inoculations. The results of the repeat experiments confirmed that the H7-expressing p188 DNA could afford protection against a lethal challenge (Table 2). In contrast to the first experiment, in which all of the p188-inoculated chickens survived the lethal challenge, immunizations in the 2nd, 3rd, and 4th experiments achieved only partial protection with from 28% to 83% of the vaccinated birds surviving. Further, in contrast to the first experiment in which vaccinated birds showed no signs of disease, most of the survivors of the repeat experiments showed transient signs of post-challenge sickness. As in the first experiment, the control DNA did not provide protection. Summing the results of the 4 experiments, 28 out of 56 p188-vaccinated birds survived whereas only 1 of 55 control DNA-inoculated birds survived. Thus, despite the variability, significant immunization was achieved.
Example 3 - Immunization can be Accomplished by Several Different Routes of Inoculation Procedure:
The DNA encoding p188-H7 and control DNA were tested again for the ability to protect against a lethal influenza virus challenge. This experiment included a group that was vaccinated and boosted by three routes of inoculation (i.e., ip, iv and sc), a group that was vaccinated by the same three routes but did not receive a boost, small groups that were vaccinated and boosted by only one route of inoculation and a control group treated with the anti-influenza virus drug, amantadine-HCL. This last group was included to allow the comparison of antibody responses to the challenge virus in vaccinated and unvaccinated chickens. The amantadine-treated birds were given 0.01% amantadine in their drinking water beginning 8 hours after challenge and were also injected ip with 1.0 ml of 0.1% amantadine 24 and 48 hours after challenge.
Results:
The results of this experiment confirmed that the replication defective H7-expressing DNA (p188) could afford protection against a lethal virus challenge (Table 3). The p188 immunized birds showed transient signs of sickness following the challenge. As in the previous experiments, the control DNA did not provide protection. All of the 5 amantadine-treated control birds developed disease. Four of these survived the challenge, providing sera that could be used to compare the time course and specificity of anti-influenza virus responses in immunized and non-immunized chickens (see Example 5 below).
The DNA encoding p188-H7 and control DNA were tested again for the ability to protect against a lethal influenza virus challenge. This experiment included a group that was vaccinated and boosted by three routes of inoculation (i.e., ip, iv and sc), a group that was vaccinated by the same three routes but did not receive a boost, small groups that were vaccinated and boosted by only one route of inoculation and a control group treated with the anti-influenza virus drug, amantadine-HCL. This last group was included to allow the comparison of antibody responses to the challenge virus in vaccinated and unvaccinated chickens. The amantadine-treated birds were given 0.01% amantadine in their drinking water beginning 8 hours after challenge and were also injected ip with 1.0 ml of 0.1% amantadine 24 and 48 hours after challenge.
Results:
The results of this experiment confirmed that the replication defective H7-expressing DNA (p188) could afford protection against a lethal virus challenge (Table 3). The p188 immunized birds showed transient signs of sickness following the challenge. As in the previous experiments, the control DNA did not provide protection. All of the 5 amantadine-treated control birds developed disease. Four of these survived the challenge, providing sera that could be used to compare the time course and specificity of anti-influenza virus responses in immunized and non-immunized chickens (see Example 5 below).
ExamRle 4 - Immunization can be Accomplished by Several Different Routes of=Inoculation Procedure:
A third experiment was initiated to increase the numbers of birds in the test groups and to further evaluate the efficacy of different routes of immunization.
In this experiment 12 chicks were inoculated with 100 g p188 by the iv, ip, and sc routes, 8 chicks were inoculated iv-only and 8 ip-only. For controls, 12 chicks were inoculated with pRCAS and 12 chicks were not inoculated. All immunizations were followed by a boost four weeks after the initial inoculation. The boosts used.
the same DNA dose and sites of inoculation as the vaccinations. The control and immunized animals were challenged with ck/vic/85 1-2 weeks after the boost, with high challenge doses used in order to achieve essentially 100% killing within 1-2 weeks.
Results:
The results again demonstrated protection by p188 (Table 4). Eight of the 12 p188 immunized birds survived, whereas all 12 of the control pRCAS chickens died. The twelve birds in the untreated control group also had no survivors. Six out of the 8 chickens inoculated iv-only with p188 survived whereas none of the 8 chickens inoculated ip-only survived.
Example 5 - Analysis of Antibody Response to Challenge Virus in Vaccinated and Unvaccinated Animals Procedure:
To allow the comparison of antibody responses to the challenge virus in vaccinated and unvaccinated chickens, experiment 2 from Example 2 (Table 2) included a non-vaccinated group rescued with the anti-influenza A virus drug, amantadine-HCL (Table 2) (Webster, R.G., et al., J.
WO 93/19183 2132~ 36 PCT/L'S93/02394 Virol. 55:173-176 (1985)). All of the 5 amantadine-treated birds developed disease. Four of these survived, providing sera that could be used to compare antibody responses in immunized and non-immunized chickens (Table 6).
Sera from p188 inoculated and amantadine treated birds in the second experiment were analyzed for the time course of antibody responses to H7 and to other influenza virus proteins (Table 6). Antibody responses to H7 were quantitated using hemagglutination inhibition as well as virus neutralization and enzyme-linked immunosorbent assays (ELISA) for antibody. Neutralizing antibody was determined in chick embryo fibroblast cultures with 200 TCID50 of virus using cytopathology and hemagglutinin for detection of virus replication.
Results:
Analysis of the antibody responses in vaccinated and amantadine-rescued birds revealed that the p188-inoculations had primed an antibody response to H7 (Table 6). As in experiment 1 (Table 1), DNA vaccination and boost induced only low titers of antibody to H7.
However, within one week of challenge, the DNA-immunized group had high titers of HI and neutralizing activity for H7. These titers underwent little (if any) increase over the next week. Furthermore, most of the post-challenge antibody in the vaccinated birds was directed against H7.
This specificity was shown by comparing ELISA antibody titers to H7 virus (the immunizing hemagglutinin type) and H5 virus (a hemagglutinin type to which the birds had not been exposed). The post-challenge sera contained 20-times higher titers of ELISA antibody for the H7 than the H5 virus (Table 6). By contrast, in the amantadine-rescued group, antibodies did not appear until two weeks post-challenge. Most of this response was not H7-specific.
A third experiment was initiated to increase the numbers of birds in the test groups and to further evaluate the efficacy of different routes of immunization.
In this experiment 12 chicks were inoculated with 100 g p188 by the iv, ip, and sc routes, 8 chicks were inoculated iv-only and 8 ip-only. For controls, 12 chicks were inoculated with pRCAS and 12 chicks were not inoculated. All immunizations were followed by a boost four weeks after the initial inoculation. The boosts used.
the same DNA dose and sites of inoculation as the vaccinations. The control and immunized animals were challenged with ck/vic/85 1-2 weeks after the boost, with high challenge doses used in order to achieve essentially 100% killing within 1-2 weeks.
Results:
The results again demonstrated protection by p188 (Table 4). Eight of the 12 p188 immunized birds survived, whereas all 12 of the control pRCAS chickens died. The twelve birds in the untreated control group also had no survivors. Six out of the 8 chickens inoculated iv-only with p188 survived whereas none of the 8 chickens inoculated ip-only survived.
Example 5 - Analysis of Antibody Response to Challenge Virus in Vaccinated and Unvaccinated Animals Procedure:
To allow the comparison of antibody responses to the challenge virus in vaccinated and unvaccinated chickens, experiment 2 from Example 2 (Table 2) included a non-vaccinated group rescued with the anti-influenza A virus drug, amantadine-HCL (Table 2) (Webster, R.G., et al., J.
WO 93/19183 2132~ 36 PCT/L'S93/02394 Virol. 55:173-176 (1985)). All of the 5 amantadine-treated birds developed disease. Four of these survived, providing sera that could be used to compare antibody responses in immunized and non-immunized chickens (Table 6).
Sera from p188 inoculated and amantadine treated birds in the second experiment were analyzed for the time course of antibody responses to H7 and to other influenza virus proteins (Table 6). Antibody responses to H7 were quantitated using hemagglutination inhibition as well as virus neutralization and enzyme-linked immunosorbent assays (ELISA) for antibody. Neutralizing antibody was determined in chick embryo fibroblast cultures with 200 TCID50 of virus using cytopathology and hemagglutinin for detection of virus replication.
Results:
Analysis of the antibody responses in vaccinated and amantadine-rescued birds revealed that the p188-inoculations had primed an antibody response to H7 (Table 6). As in experiment 1 (Table 1), DNA vaccination and boost induced only low titers of antibody to H7.
However, within one week of challenge, the DNA-immunized group had high titers of HI and neutralizing activity for H7. These titers underwent little (if any) increase over the next week. Furthermore, most of the post-challenge antibody in the vaccinated birds was directed against H7.
This specificity was shown by comparing ELISA antibody titers to H7 virus (the immunizing hemagglutinin type) and H5 virus (a hemagglutinin type to which the birds had not been exposed). The post-challenge sera contained 20-times higher titers of ELISA antibody for the H7 than the H5 virus (Table 6). By contrast, in the amantadine-rescued group, antibodies did not appear until two weeks post-challenge. Most of this response was not H7-specific.
This was demonstrated by the post-challenge sera from the amantadine-rescued birds which had comparable titers of ELISA antibody for the H5 and the H7 influenza viruses.
(Table 6).
Example 6 - Immunization of Chickens and Mice Using a Nonretroviral Transcription Unit Procedure This experiment was performed in order to demonstrate that DNA transcription units devoid of retroviral DNA could be successfully employed to generate a protective immune response in both chickens and mice according to the methods herein described.
The vectors used in this experiment to vaccinate chicken and mice are shown in Figure 4A-4C. Figure 4A
is a schematic representation of pCMV-H7, a plasmid capable of expressing the influenza virus H7 subtype hemagglutinin under the transcription control of a cytomegalovirus (CMV) immediate early promoter. Figure 4B is a schematic showing pCMV-H1, a plasmid capable of expressing the influenza virus Hl subtype hemagglutinin under the control of a CMV immediate early promoter.
This is the DNA transcription unit used in the mouse experiments. Figure 4C shows pCMV, a control plasmid which is not capable of expressing influenza antigens.
These plasmids are derivatives of the pBC12/CMV vector of Dr. Brian Cullen, Duke University, Durham, North Carolina.
In the chicken and mouse experiments using pCMV-H7 and pCMV-H1 DNAs (the nonretroviral-based DNA
transcription units) to generate immune responses, 100 g of DNA was inoculated intravenously, intraperitoneally, and intramuscularly. All vaccinations were followed by a boost 4 weeks later.
The boosts used the same DNA dose and sites of .
(Table 6).
Example 6 - Immunization of Chickens and Mice Using a Nonretroviral Transcription Unit Procedure This experiment was performed in order to demonstrate that DNA transcription units devoid of retroviral DNA could be successfully employed to generate a protective immune response in both chickens and mice according to the methods herein described.
The vectors used in this experiment to vaccinate chicken and mice are shown in Figure 4A-4C. Figure 4A
is a schematic representation of pCMV-H7, a plasmid capable of expressing the influenza virus H7 subtype hemagglutinin under the transcription control of a cytomegalovirus (CMV) immediate early promoter. Figure 4B is a schematic showing pCMV-H1, a plasmid capable of expressing the influenza virus Hl subtype hemagglutinin under the control of a CMV immediate early promoter.
This is the DNA transcription unit used in the mouse experiments. Figure 4C shows pCMV, a control plasmid which is not capable of expressing influenza antigens.
These plasmids are derivatives of the pBC12/CMV vector of Dr. Brian Cullen, Duke University, Durham, North Carolina.
In the chicken and mouse experiments using pCMV-H7 and pCMV-H1 DNAs (the nonretroviral-based DNA
transcription units) to generate immune responses, 100 g of DNA was inoculated intravenously, intraperitoneally, and intramuscularly. All vaccinations were followed by a boost 4 weeks later.
The boosts used the same DNA dose and sites of .
inoculation as the vaccinations. Challenge was 1-2 weeks after the boost, with high challenge doses being used so as to achieve essentially 100% killing within 1-2 weeks.
Results:
Ia five chicken trials using a nonretrovirus-based vector for vaccination (pCMV-H7) (Figure 4A), approximately 60% of the chickens were protected. In one mouse trial, six out of six vaccinated mice and only one out of six control mice survived. Thus, considerable protection has been achieved using nonretroviral DNA expression vectors (containing DNA
transcription units encoding viral antigens) to vaccinate animals. See, for example, Table 5.
In the chicken experiments, protective responses were associated with the rapid appearance of H7-specific antibodies after challenge (Robinson gt ~., Vaccine 11:957-960, 1993). Sera contained low to undetectable levels of anti-H7 antibodies after vaccination and boost. The first mouse experiment was similar to the chicken experiments in that inoculated mice also had low titers of anti-hemagglutinin activity before challenge.
However, as in the chicken experiments, high titers of antibody appeared after challenge. The vast majority of this antibody was IgG.
Example 7- Immunization of Mice by Vaccination with a onretroviral Transcriotion Unit: Analysis of Various Routes of Inoculation Procedure:
A DNA transcription unit referred to as pCMV-H1 (described in Figure 4B) was successfully used to immunize mice against a lethal challenge with mouse adapted A/PR/8/34 H1N1 influenza virus. This transcription unit encodes an influenza type H1 hemagglutinin under the transcription regulation of a CMV immediate early promoter. The Hi influenza virus hemagglutinin gene used in this construct is described in more detail in Winters gt kl., Nature M:72 (1981.).
The first experiment was conducted by inoculation of 6-8 week old Balb/C mice with 100 q of pCMV-Hl DNA
by each of three routes; iv, ip and im. The second, third and fourth experiments each included one group of mice inoculated iv, ip and im, as well as additional groups representing different routes of inoculation (data summarized in Table 7 and Figure 5).
The numbers in Table 7 represent the number of surviving mice/number of inoculated mice. The routes of inoculation (iv, intravenous; ip, intraperitoneal;
im, intramuscular; sc., subcutaneous;.in, intranasal;
id, intradermal) for each trial are indicated. In most instances, 100 g of DNA was administered per injection. Intramuscular (im) inoculations were given by injection of 100 pg DNA in each hip muscle.
Intravenous (iv) inoculations were given by injection in the tail vein. Intranasal (in) administrations of DNA and challenges were done on Metofane anesthetized animals (Pitman-Moore) (these animals inhale deeply).
Intradermal (id) inoculations were done in the foot pad using only 50 pg of DNA. The control groups in experiments 2 and 3 received saline. The controls for experiment 1 received control DNA (vector without an insert encoding the antigen) administered iv, ip and im. The control group in experiment 4 received control DNA im, in and id. Occasional mice are resistant to influenza challenge. One of the survivors in the intranasal group in experiment 2, the one survivor in the control group in experiment 1, and 1 survivor in the control group in experiment 4 were such resistant * trade-mark mice. All groups showed signs of sickness following challenge. Data on weight loss were also collected and are presented in Figure 5. The weight loss data provides a quantitative measure for the degree of sickness in the different experimental groups.
Results:
The survival data, weight loss data and initial serology data from this series of experiments indicate that many routes of inoculation can provide protective immunity. In addition, these data demonstrate that intranasal inoculation (DNA nose drops administered to Metofane-anesthetized mice) -can provide protective immunity to a lethal virus challenge. The method herein described may, therefore, provide means of stimulating mucosal immunity. (Table 7 and Figure 5].
Finally, these data demonstrate that some routes of inoculation are more effective than others for generating a protective immune response (Table 8).
Example 8 - Antibody Responses to Challenge Virus in Animals Vaccinated with a Nonretroviral DNA Transcription Unit Experiments analyzing the serum response in pCMV-H7-vaccinated chickens were performed as described in Example 4. pCMV-H7 immunizations primed antibody responses, with high titers of antibody to H7 appearing post-challenge (Table 9).
WO 93/19183 2132836 PCT/L'S93/0239 TABLE 1 Protection Against Lethal H7N7 Influenza Virus with DNA Coding for H7 Hemagglutinin HI TITERS
Group Sick/Dead/Total Post- Post- Post-vaccine boost Challenge 4 weeks 1 week 1.5 weeks pPl/H7 0/0/6 <.a <. 864 (160-1280) p188 0/0/6 <b < 427 (160-1280) pRCAS 6/6/6 < < +
a(<.) means one of six birds had an HI titer of 10.
b(<) means that all birds had titers of less than 10.
c (+) means that all birds died.
"VO 93/19183 2132336 PCT/US93/02394 C
O m w Q) C
~ N ~ ~ >. 3 O ~
t; rd 14 ~ A ~ -+
~- 3 4) m w a >. b O 0 a ~-+ a) x A ar -W m -14 +J 0 u ~ .r, a~i C z o c~ o 41 c ~i , ~ -~ ~ 0 .a ~ m N N
~ ~ ~ ~ c m o a) = ~ a~
=H b 1~ "I U 0 S-r U W -r1 > 3-I wI I I O O 0 IT Gl tA r-1 Vi ~ A w 4-) 10 O+1 S 4..! 0 74 c O c .-4 ~ z v o b ~ r-i a +) a 4 m to 4 .C --1 +) ~
~ w t0 N ~ -rl ~C
0 --v7 > ~ ai 3 oi > 3 ~
=.1 d ~ d 4-) -=~ v) rts ~ > c =~ 3 2s ro a~ v s4 -4 U, Ul) +-) Z 0 b 0 +) Ul to ~ 1 v I 1 d' 41 3 oU) wzC) C _q x d w -.i tT W ~ 0 0 4) 4-) (L) W
vi w (1) ~ ~ 3~~ m m a~ w ~ .~ sa =.~ ~a w f~ 4) a~ ~ ~-=~ S 4 -~ C~ +~ ~ ~ f~ b 10 > >
41 x v --+
U G) ~- .C 3 4 QI >
d 1 +) V = Z tyN 3-i +-) r- a Z G r. z s a 0 N N In ro ~ U vUi w~ ~
a ~ w cn ~D LO n f-1 t, =.q =~ . 0 r-I 0) ro tp 4 a) 14. ~ 10 ro F:
w U O ri O O rl 04) U rtt+ .C O
O0) C 4) fx (o a b 0 zt U m >. - r. a N o) 4-) a a O O
1~ ~ Gl O tA fj. -rq O W =
=r1 0 ~ U) > O Z uN
.0 .-1 tn ~ 4-) -4 +J to r 9 -~ +) U ==~ 0 0 'Lf - =-I r. = 0 U to 0 r. P-4 3 O- =H
:% N 4-4 z k0 r=1 0 0 tA 1!4 1J
z3 =+ 0 Ca N N Ln A I a) C U U) U
0 C %D %c m -q -- 4-) 1' x+) O -~ co 4) 14 7 O ao oo c 11 Q) :1 -4 .C -- 44 M O 4-) CO 10 U) Q1 OD N Q)UI C) O 1jC) U r-a H w 7-4 =~ ~, " a s~ ro~ -H
1 p .~G ~ Cl 0~) U ~
G7 x z N x 4) to C.C C ro\-r1 I W 3 (n E+ +-) =~ -4 Q >
a) ~ ro a 0 H N C1 tT 1}
k rz 0 E-~ W =-I E-+ ro TABLE 3 Protection Against Lethal H7N7 Influenza Virus with DNA Coding for H7 Hemagglutinin Group Route of Boost Sick/Dead/Totala Inoculation p188 ip/iv/sc yes 6/1/6 p188 iv only yes 1/1/2 p188 ip only yes 0/0/2 p188 sc only yes 2/2/2 pRCAS ip/iv/sc yes 5/4/5 none NAb NA
none NA NA 5/1/5 Aman.
----------- ------------------------ --------------------------------------------------p188 iv/ip/sc no 4/4/6 pRCAS iv/ip/sc no 6/6/6 a Sick birds that survived developed only mild signs of sickness such as ruffled feathers and temporary loss of appetite.
b (NA) not applicable.
c (Aman.) is an abbreviation for Amantadine.
%"O 93/19183 PCT/US93/02394 ~
O N
w rtf =U
=,~
b N
tn N
Oi =rl }7 tA
-~
3 ~ N N 44 Q) r1 rl 0 Vl p N \ \
\ ~i CO CO N N N
=~ U ~ N co \ \ =b+ ~
'/ =.i \ \ \ N N
N~
U) N 00 e-1 r4 N b 4J
=rl CL
r~-1 R1 %4 N
z 00 ca >4 0) 0 P4 ~
~ 0 > to (L) o ~
4-) ~~
0 bN r. 0 1d N >+ >4 tA to a' ==i .-4 \ r-1 r i \ N N fd ~ i~ U ~ ~ 0 O -a 4J W U
~ 0 O G > > P. > r. .C ' i*
o c a F-+ -rl -.i -ri =H z 4-' ~ ~4i 4) O+ N O ~d Sa G~l -O 0 a x A ~ ~
r-i _ ~ U v-w =1-1 0 z 0 0 0 o cai ~
aa f ~ .-i H ri x 0 a a s~ a~
E, ro n WO 93/19183 2132836 PCT/L'S93/0231 ' TABLE 5 Protection Against a Lethal H7 Influenza Virus Challenge by Immunization with pCMV-H7 DNA.
Fate of challenge group (number of survivors/number tested) Trial pCMV-H7 DNA pCMV DNA
Total 19/30 1/33 Immunization and boosts were the same as in Table 2.
Some survivors developed transient signs of influenza-related illness.
"VO 93/19183 2132836 PCT/US93/02394 ~
co ~. ~
o O r- I --41 cn 0 -- 0 r-1 . =i 0 0 ~. ~ x 0 0 '~ ~ ... rl r-1 O C~
A ~
al ir rN~ ~ p tl) i p 4-1 ' U1 H 0 U x W V V N e! v v r-1 .-. .=.
O O
~ O O ~
=~ p .-1 ri 0 X .. .=- O 0 0 O O H
H H
cn O O O
to a) O 0 0 ~4 0 E4 W N 1n w w V V V ~--1 C) ,d .=. .. 0 ro c'1 O O
~ 0 ~ el) O O
r. 4.1 =ri e'1 0 to to N .-. tn ~ >y CO =rl .. C1 I 1 O . .
'Cf -, H 0 m m C1 O U.. ro H I cn rn ,~ O ... .~ .. A
b .0 ''/ z V p ~ - v rf 0 44 ~f ai ~ N CO !f1 V V 'd' v0 y U ."r.~ H
G) G1 rz ..a ro 4 ~n C .~ .-. .-= '~ 4.) 4) 'O = -1 F. ri ~0 %O to b% W
O O O O 0 a. d O
r ~ N o0 00 00 4j O to 4 k v v v ~ 0 N N 0 [f-0r. +1 =.~i H ri I, 'C 0 to A U=.i U1 00 rl N v v v c"1 ~-~ 1J
iJ 4-) n~
N > t1100~
a ~ V iL ~L .C
~ a a a a a a a a ~~b a ro aroiaroi~
~ aroJ 3 3 3 3 3 3 3 3 44 3 3A
O
(~ H N H N rl N r-I N N
4) 4 4J~rororo 4J Vl Z 1C ~D tf1 l!~ U1 ln d qq >y z ~ A a a a) ,~ .
co o~ +~za3v c~ zQ ~ro0 ov ~o a \ \
=~+ O O
~
%D
U U \ \
CL N ~ v ~
=,.{
!A N
b \ \ \
N ==~ ~c M rn H
.,i E '==~
~0 ~0 \
C \ \ O
0 -=~ -~r %o W-+
=,=~
ri C 0 ~o ~o ~n \
O ~ \ \ \ M
~ =rl 10 M d e=i tl1 Q -rl Q~
z > W-+
%o %c c~ \
b \ \ \ oo ~1 N .-1 !fl ~D f~ r-1 0 d L*r :3 a N
$-I W =rl N
W H
\ =rl -rl 10 t0 %0 M N
fo 41 4.) G
1~ =.=1 r-I
fd ~1 ~O 1D ~O ~O N
> C) .N \ \ \ \ \
=ri ,C r. ri O O N M
3>-~ 4J U
O C
n /-"1 r-I N M d e--I
w w M a-W
w x x xx 0 H H 41 C1 0 0 E+
Results:
Ia five chicken trials using a nonretrovirus-based vector for vaccination (pCMV-H7) (Figure 4A), approximately 60% of the chickens were protected. In one mouse trial, six out of six vaccinated mice and only one out of six control mice survived. Thus, considerable protection has been achieved using nonretroviral DNA expression vectors (containing DNA
transcription units encoding viral antigens) to vaccinate animals. See, for example, Table 5.
In the chicken experiments, protective responses were associated with the rapid appearance of H7-specific antibodies after challenge (Robinson gt ~., Vaccine 11:957-960, 1993). Sera contained low to undetectable levels of anti-H7 antibodies after vaccination and boost. The first mouse experiment was similar to the chicken experiments in that inoculated mice also had low titers of anti-hemagglutinin activity before challenge.
However, as in the chicken experiments, high titers of antibody appeared after challenge. The vast majority of this antibody was IgG.
Example 7- Immunization of Mice by Vaccination with a onretroviral Transcriotion Unit: Analysis of Various Routes of Inoculation Procedure:
A DNA transcription unit referred to as pCMV-H1 (described in Figure 4B) was successfully used to immunize mice against a lethal challenge with mouse adapted A/PR/8/34 H1N1 influenza virus. This transcription unit encodes an influenza type H1 hemagglutinin under the transcription regulation of a CMV immediate early promoter. The Hi influenza virus hemagglutinin gene used in this construct is described in more detail in Winters gt kl., Nature M:72 (1981.).
The first experiment was conducted by inoculation of 6-8 week old Balb/C mice with 100 q of pCMV-Hl DNA
by each of three routes; iv, ip and im. The second, third and fourth experiments each included one group of mice inoculated iv, ip and im, as well as additional groups representing different routes of inoculation (data summarized in Table 7 and Figure 5).
The numbers in Table 7 represent the number of surviving mice/number of inoculated mice. The routes of inoculation (iv, intravenous; ip, intraperitoneal;
im, intramuscular; sc., subcutaneous;.in, intranasal;
id, intradermal) for each trial are indicated. In most instances, 100 g of DNA was administered per injection. Intramuscular (im) inoculations were given by injection of 100 pg DNA in each hip muscle.
Intravenous (iv) inoculations were given by injection in the tail vein. Intranasal (in) administrations of DNA and challenges were done on Metofane anesthetized animals (Pitman-Moore) (these animals inhale deeply).
Intradermal (id) inoculations were done in the foot pad using only 50 pg of DNA. The control groups in experiments 2 and 3 received saline. The controls for experiment 1 received control DNA (vector without an insert encoding the antigen) administered iv, ip and im. The control group in experiment 4 received control DNA im, in and id. Occasional mice are resistant to influenza challenge. One of the survivors in the intranasal group in experiment 2, the one survivor in the control group in experiment 1, and 1 survivor in the control group in experiment 4 were such resistant * trade-mark mice. All groups showed signs of sickness following challenge. Data on weight loss were also collected and are presented in Figure 5. The weight loss data provides a quantitative measure for the degree of sickness in the different experimental groups.
Results:
The survival data, weight loss data and initial serology data from this series of experiments indicate that many routes of inoculation can provide protective immunity. In addition, these data demonstrate that intranasal inoculation (DNA nose drops administered to Metofane-anesthetized mice) -can provide protective immunity to a lethal virus challenge. The method herein described may, therefore, provide means of stimulating mucosal immunity. (Table 7 and Figure 5].
Finally, these data demonstrate that some routes of inoculation are more effective than others for generating a protective immune response (Table 8).
Example 8 - Antibody Responses to Challenge Virus in Animals Vaccinated with a Nonretroviral DNA Transcription Unit Experiments analyzing the serum response in pCMV-H7-vaccinated chickens were performed as described in Example 4. pCMV-H7 immunizations primed antibody responses, with high titers of antibody to H7 appearing post-challenge (Table 9).
WO 93/19183 2132836 PCT/L'S93/0239 TABLE 1 Protection Against Lethal H7N7 Influenza Virus with DNA Coding for H7 Hemagglutinin HI TITERS
Group Sick/Dead/Total Post- Post- Post-vaccine boost Challenge 4 weeks 1 week 1.5 weeks pPl/H7 0/0/6 <.a <. 864 (160-1280) p188 0/0/6 <b < 427 (160-1280) pRCAS 6/6/6 < < +
a(<.) means one of six birds had an HI titer of 10.
b(<) means that all birds had titers of less than 10.
c (+) means that all birds died.
"VO 93/19183 2132336 PCT/US93/02394 C
O m w Q) C
~ N ~ ~ >. 3 O ~
t; rd 14 ~ A ~ -+
~- 3 4) m w a >. b O 0 a ~-+ a) x A ar -W m -14 +J 0 u ~ .r, a~i C z o c~ o 41 c ~i , ~ -~ ~ 0 .a ~ m N N
~ ~ ~ ~ c m o a) = ~ a~
=H b 1~ "I U 0 S-r U W -r1 > 3-I wI I I O O 0 IT Gl tA r-1 Vi ~ A w 4-) 10 O+1 S 4..! 0 74 c O c .-4 ~ z v o b ~ r-i a +) a 4 m to 4 .C --1 +) ~
~ w t0 N ~ -rl ~C
0 --v7 > ~ ai 3 oi > 3 ~
=.1 d ~ d 4-) -=~ v) rts ~ > c =~ 3 2s ro a~ v s4 -4 U, Ul) +-) Z 0 b 0 +) Ul to ~ 1 v I 1 d' 41 3 oU) wzC) C _q x d w -.i tT W ~ 0 0 4) 4-) (L) W
vi w (1) ~ ~ 3~~ m m a~ w ~ .~ sa =.~ ~a w f~ 4) a~ ~ ~-=~ S 4 -~ C~ +~ ~ ~ f~ b 10 > >
41 x v --+
U G) ~- .C 3 4 QI >
d 1 +) V = Z tyN 3-i +-) r- a Z G r. z s a 0 N N In ro ~ U vUi w~ ~
a ~ w cn ~D LO n f-1 t, =.q =~ . 0 r-I 0) ro tp 4 a) 14. ~ 10 ro F:
w U O ri O O rl 04) U rtt+ .C O
O0) C 4) fx (o a b 0 zt U m >. - r. a N o) 4-) a a O O
1~ ~ Gl O tA fj. -rq O W =
=r1 0 ~ U) > O Z uN
.0 .-1 tn ~ 4-) -4 +J to r 9 -~ +) U ==~ 0 0 'Lf - =-I r. = 0 U to 0 r. P-4 3 O- =H
:% N 4-4 z k0 r=1 0 0 tA 1!4 1J
z3 =+ 0 Ca N N Ln A I a) C U U) U
0 C %D %c m -q -- 4-) 1' x+) O -~ co 4) 14 7 O ao oo c 11 Q) :1 -4 .C -- 44 M O 4-) CO 10 U) Q1 OD N Q)UI C) O 1jC) U r-a H w 7-4 =~ ~, " a s~ ro~ -H
1 p .~G ~ Cl 0~) U ~
G7 x z N x 4) to C.C C ro\-r1 I W 3 (n E+ +-) =~ -4 Q >
a) ~ ro a 0 H N C1 tT 1}
k rz 0 E-~ W =-I E-+ ro TABLE 3 Protection Against Lethal H7N7 Influenza Virus with DNA Coding for H7 Hemagglutinin Group Route of Boost Sick/Dead/Totala Inoculation p188 ip/iv/sc yes 6/1/6 p188 iv only yes 1/1/2 p188 ip only yes 0/0/2 p188 sc only yes 2/2/2 pRCAS ip/iv/sc yes 5/4/5 none NAb NA
none NA NA 5/1/5 Aman.
----------- ------------------------ --------------------------------------------------p188 iv/ip/sc no 4/4/6 pRCAS iv/ip/sc no 6/6/6 a Sick birds that survived developed only mild signs of sickness such as ruffled feathers and temporary loss of appetite.
b (NA) not applicable.
c (Aman.) is an abbreviation for Amantadine.
%"O 93/19183 PCT/US93/02394 ~
O N
w rtf =U
=,~
b N
tn N
Oi =rl }7 tA
-~
3 ~ N N 44 Q) r1 rl 0 Vl p N \ \
\ ~i CO CO N N N
=~ U ~ N co \ \ =b+ ~
'/ =.i \ \ \ N N
N~
U) N 00 e-1 r4 N b 4J
=rl CL
r~-1 R1 %4 N
z 00 ca >4 0) 0 P4 ~
~ 0 > to (L) o ~
4-) ~~
0 bN r. 0 1d N >+ >4 tA to a' ==i .-4 \ r-1 r i \ N N fd ~ i~ U ~ ~ 0 O -a 4J W U
~ 0 O G > > P. > r. .C ' i*
o c a F-+ -rl -.i -ri =H z 4-' ~ ~4i 4) O+ N O ~d Sa G~l -O 0 a x A ~ ~
r-i _ ~ U v-w =1-1 0 z 0 0 0 o cai ~
aa f ~ .-i H ri x 0 a a s~ a~
E, ro n WO 93/19183 2132836 PCT/L'S93/0231 ' TABLE 5 Protection Against a Lethal H7 Influenza Virus Challenge by Immunization with pCMV-H7 DNA.
Fate of challenge group (number of survivors/number tested) Trial pCMV-H7 DNA pCMV DNA
Total 19/30 1/33 Immunization and boosts were the same as in Table 2.
Some survivors developed transient signs of influenza-related illness.
"VO 93/19183 2132836 PCT/US93/02394 ~
co ~. ~
o O r- I --41 cn 0 -- 0 r-1 . =i 0 0 ~. ~ x 0 0 '~ ~ ... rl r-1 O C~
A ~
al ir rN~ ~ p tl) i p 4-1 ' U1 H 0 U x W V V N e! v v r-1 .-. .=.
O O
~ O O ~
=~ p .-1 ri 0 X .. .=- O 0 0 O O H
H H
cn O O O
to a) O 0 0 ~4 0 E4 W N 1n w w V V V ~--1 C) ,d .=. .. 0 ro c'1 O O
~ 0 ~ el) O O
r. 4.1 =ri e'1 0 to to N .-. tn ~ >y CO =rl .. C1 I 1 O . .
'Cf -, H 0 m m C1 O U.. ro H I cn rn ,~ O ... .~ .. A
b .0 ''/ z V p ~ - v rf 0 44 ~f ai ~ N CO !f1 V V 'd' v0 y U ."r.~ H
G) G1 rz ..a ro 4 ~n C .~ .-. .-= '~ 4.) 4) 'O = -1 F. ri ~0 %O to b% W
O O O O 0 a. d O
r ~ N o0 00 00 4j O to 4 k v v v ~ 0 N N 0 [f-0r. +1 =.~i H ri I, 'C 0 to A U=.i U1 00 rl N v v v c"1 ~-~ 1J
iJ 4-) n~
N > t1100~
a ~ V iL ~L .C
~ a a a a a a a a ~~b a ro aroiaroi~
~ aroJ 3 3 3 3 3 3 3 3 44 3 3A
O
(~ H N H N rl N r-I N N
4) 4 4J~rororo 4J Vl Z 1C ~D tf1 l!~ U1 ln d qq >y z ~ A a a a) ,~ .
co o~ +~za3v c~ zQ ~ro0 ov ~o a \ \
=~+ O O
~
%D
U U \ \
CL N ~ v ~
=,.{
!A N
b \ \ \
N ==~ ~c M rn H
.,i E '==~
~0 ~0 \
C \ \ O
0 -=~ -~r %o W-+
=,=~
ri C 0 ~o ~o ~n \
O ~ \ \ \ M
~ =rl 10 M d e=i tl1 Q -rl Q~
z > W-+
%o %c c~ \
b \ \ \ oo ~1 N .-1 !fl ~D f~ r-1 0 d L*r :3 a N
$-I W =rl N
W H
\ =rl -rl 10 t0 %0 M N
fo 41 4.) G
1~ =.=1 r-I
fd ~1 ~O 1D ~O ~O N
> C) .N \ \ \ \ \
=ri ,C r. ri O O N M
3>-~ 4J U
O C
n /-"1 r-I N M d e--I
w w M a-W
w x x xx 0 H H 41 C1 0 0 E+
ro N N =
G >. o 0m rNi ~
0 it w aUi v v v v Nr ~+ ~
.4 N
N =,},.
0 0+~
0 0 w =~
-~ vv vv vv vv ~~ =~~
3.a.i U ~
av ~
LO
~-+ o o 44 a) > o o N~ 10 O U
I =r1 v v v v v v oD m ko a) =.i ~ C E
O O
U O -,-4 tP
o0o ap,~O+
W d d 3-1 (1 >
0 -=-1 V V V V V V V V V V V cn %o %O O U=-I
O w >
-~ -1 G) N
RS ~ O O N N d fz 47 O
=-+ ==~ v v v v v v v v v v-cr chcl %e +-) U
W =~ ic =~ 0000 --~ = ~ 10 c?' %0 d 'J R 0 00 0 lf1 ~D r-1 %D I~ M =
ON =~ -= 4 V V V V V V d V Vv CO V 00 V 0 C GI co =rl .=-1 -1 0 r-i fv fo O
r-i 0 Ea H
r-i w w 0 ~ a iz Q1 fir r.. ~c rl =.4 jJ
0 ic Ic =.-4 vl U V V V V V V V V V V V V V V 't3 ~0 't! '~ 't (1) +) Ol 4-) O (C
4J w C
=~ O 41 'O
N r.
' =~ s+ (s a) O S-1 V! ~ U) .a P r-I NMd' e=1NMd r-1NC1ICT r=1NMd' r4 Nf"iqc7 r4 ~l -r1 rtt (c O
a -- 4-) (L) H b~ f-1 4J -H
0 a) =~
x -, a i a w +1 P-4 U w >
to aa -4 b >, (t ~+
co w G) > 0 rt1 z3 D) b a.00 ~~ b rn r0 a a~ a~ . .x v 10 (1) ,-a O v v W ~ a~ a~ 3 w w Ln i ~+ +) C
a =H ~q p, o f1, i Nr a) --+ O
H H.t2 W r-I=- r-4 En 4J *
G >. o 0m rNi ~
0 it w aUi v v v v Nr ~+ ~
.4 N
N =,},.
0 0+~
0 0 w =~
-~ vv vv vv vv ~~ =~~
3.a.i U ~
av ~
LO
~-+ o o 44 a) > o o N~ 10 O U
I =r1 v v v v v v oD m ko a) =.i ~ C E
O O
U O -,-4 tP
o0o ap,~O+
W d d 3-1 (1 >
0 -=-1 V V V V V V V V V V V cn %o %O O U=-I
O w >
-~ -1 G) N
RS ~ O O N N d fz 47 O
=-+ ==~ v v v v v v v v v v-cr chcl %e +-) U
W =~ ic =~ 0000 --~ = ~ 10 c?' %0 d 'J R 0 00 0 lf1 ~D r-1 %D I~ M =
ON =~ -= 4 V V V V V V d V Vv CO V 00 V 0 C GI co =rl .=-1 -1 0 r-i fv fo O
r-i 0 Ea H
r-i w w 0 ~ a iz Q1 fir r.. ~c rl =.4 jJ
0 ic Ic =.-4 vl U V V V V V V V V V V V V V V 't3 ~0 't! '~ 't (1) +) Ol 4-) O (C
4J w C
=~ O 41 'O
N r.
' =~ s+ (s a) O S-1 V! ~ U) .a P r-I NMd' e=1NMd r-1NC1ICT r=1NMd' r4 Nf"iqc7 r4 ~l -r1 rtt (c O
a -- 4-) (L) H b~ f-1 4J -H
0 a) =~
x -, a i a w +1 P-4 U w >
to aa -4 b >, (t ~+
co w G) > 0 rt1 z3 D) b a.00 ~~ b rn r0 a a~ a~ . .x v 10 (1) ,-a O v v W ~ a~ a~ 3 w w Ln i ~+ +) C
a =H ~q p, o f1, i Nr a) --+ O
H H.t2 W r-I=- r-4 En 4J *
ro a~
~ i U) Ln U) oU-) o n o 4-) ~p = = %ooc- o 00 ~ H=='~ V V V V V V N N f- ="4 ~
r = ~ $=t >
f]+ O ~ ~ 3 U
~ =.~-1 1 =N to =rl N d 41.,~ ri ri r~ o U w p ~ z~~ VVVv VVVV rn c=~r"~,~ UG) o z >~~
r, ~ a, o a ~ a~b Ln tn 1n 00 4) ooo~ r-i cn V V V V V N N %D %O H."1 a~a N == U A
O +1 1-4 ='~ wtAO
c a+ ~.
U 1-) U
~ k H
H~ V V V V V V V V O C] O Ll O
C 4.) W k cn o U '1 ~ O ~
0 G) ~ C
~N
=~i =,~ tA H
-~.C
9 ~ ~ ~
C~ G Ca Ll N~
~ ~ 0 ~ V V V V V V V V ~
U I Z w b=r. ~
r-I
U U 4) O
> ~
>
f~ ~ O ~4 a~ v x v v v v vvvv o00o a) w 41 -~o ~ 0 ~'o ~
w-14 ,n ~ A
41 =rl NMd'lf1 NC'1d'Ul NMd'l11 a c H
~ .. os a~
~ =.=1 {j N
I
ti) 41 r. =.-i (A u-+ > 0 fA G U iC O=-4 0 W 0 a G) LL G Uto a a~~ x~ xa~~ x 4.J
=0344 a,~ UO~
H HA er- ~'~U N O=K Z
'vO 93/19183 2132836 PCT/US93/02394 Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other such equivalents are intended to be encompassed by the following claims.
~ i U) Ln U) oU-) o n o 4-) ~p = = %ooc- o 00 ~ H=='~ V V V V V V N N f- ="4 ~
r = ~ $=t >
f]+ O ~ ~ 3 U
~ =.~-1 1 =N to =rl N d 41.,~ ri ri r~ o U w p ~ z~~ VVVv VVVV rn c=~r"~,~ UG) o z >~~
r, ~ a, o a ~ a~b Ln tn 1n 00 4) ooo~ r-i cn V V V V V N N %D %O H."1 a~a N == U A
O +1 1-4 ='~ wtAO
c a+ ~.
U 1-) U
~ k H
H~ V V V V V V V V O C] O Ll O
C 4.) W k cn o U '1 ~ O ~
0 G) ~ C
~N
=~i =,~ tA H
-~.C
9 ~ ~ ~
C~ G Ca Ll N~
~ ~ 0 ~ V V V V V V V V ~
U I Z w b=r. ~
r-I
U U 4) O
> ~
>
f~ ~ O ~4 a~ v x v v v v vvvv o00o a) w 41 -~o ~ 0 ~'o ~
w-14 ,n ~ A
41 =rl NMd'lf1 NC'1d'Ul NMd'l11 a c H
~ .. os a~
~ =.=1 {j N
I
ti) 41 r. =.-i (A u-+ > 0 fA G U iC O=-4 0 W 0 a G) LL G Uto a a~~ x~ xa~~ x 4.J
=0344 a,~ UO~
H HA er- ~'~U N O=K Z
'vO 93/19183 2132836 PCT/US93/02394 Equivalents Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other such equivalents are intended to be encompassed by the following claims.
Claims (15)
1. Use of a polynucleotide sequence consisting essentially of a DNA encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, and wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate.
2. Use of a polynucleotide sequence consisting of a DNA
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, and wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate.
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, and wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate.
3. Use of a polynucleotide sequence comprising a DNA
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence is free of a viral vector for vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, and wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate.
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence is free of a viral vector for vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, and wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate.
4. The use according to any one of claims 1 to 3, wherein the polynucleotide sequence, in a physiologically acceptable carrier, is adapted for administration to a vertebrate through a route chosen from mucosal, intranasal, intravenous, intramuscular, intraperitoneal, intradermal or subcutaneous administration.
5. The use according to any one of claims 1 to 4, wherein the polynucleotide sequence is adapted for mucosal surface administration to a vertebrate.
6. The use according to claim 5, wherein said mucosal surface is a nasal surface.
7. Use of a polynucleotide sequence consisting essentially of a DNA encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for the manufacture of a medicament for use in vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate, and wherein the medicament is free of a viral vector.
8. Use of a polynucleotide sequence consisting of a DNA
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for the manufacture of a medicament for use in vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate, and wherein the medicament is free of a viral vector.
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, for the manufacture of a medicament for use in vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate, and wherein the medicament is free of a viral vector.
9. Use of a polynucleotide sequence comprising a DNA
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence is free of a viral vector for the manufacture of a medicament for use in vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate, and wherein the medicament is free of a viral vector.
encoding an influenza virus antigen operatively linked to a promoter region, and optionally one or more bacterial plasmid sequences, wherein the polynucleotide sequence is free of a viral vector for the manufacture of a medicament for use in vertebrate immunization, wherein the influenza virus antigen is an influenza virus hemagglutinin protein, wherein expression of the polynucleotide sequence elicits a protective immune response against the influenza virus in a vertebrate, and wherein the medicament is free of a viral vector.
10. The use according to any one of claims 7 to 9, wherein the medicament comprises a physiologically acceptable carrier and is suitable for administration by a route chosen from mucosal, intranasal, intravenous, intramuscular, intraperitoneal, intradermal or subcutaneous administration.
11. The use according to any one of claims 7 to 10, wherein the medicament is suitable for mucosal surface administration.
12. The use according to claim 11, wherein the mucosal surface is a nasal surface.
13. The use according to any one of claims 1 to 12, wherein the hemagglutinin protein is subtype H1 or H7.
14. The use according to any one of claims 1 to 13, wherein the vertebrate is a mammal.
15. The use according to claim 14, wherein the mammal is a human.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US855,562 | 1986-04-25 | ||
US85556292A | 1992-03-23 | 1992-03-23 | |
US08/009,833 US5643578A (en) | 1992-03-23 | 1993-01-27 | Immunization by inoculation of DNA transcription unit |
US009,833 | 1993-01-27 | ||
PCT/US1993/002394 WO1993019183A1 (en) | 1992-03-23 | 1993-03-17 | Immunization by inoculatioon of dna transcription unit |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2132836A1 CA2132836A1 (en) | 1993-09-30 |
CA2132836C true CA2132836C (en) | 2008-07-08 |
Family
ID=26679920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002132836A Expired - Fee Related CA2132836C (en) | 1992-03-23 | 1993-03-17 | Immunization by inoculation of dna transcription unit |
Country Status (5)
Country | Link |
---|---|
US (3) | US5643578A (en) |
EP (1) | EP0633937A1 (en) |
JP (3) | JPH07507203A (en) |
CA (1) | CA2132836C (en) |
WO (1) | WO1993019183A1 (en) |
Families Citing this family (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US20040087521A1 (en) * | 1993-03-18 | 2004-05-06 | Merck & Co., Inc. | Nucleic acid pharmaceuticals-influenza matrix |
IL108915A0 (en) * | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
FR2711670B1 (en) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
US6133244A (en) | 1993-10-22 | 2000-10-17 | Institut Pasteur | Method for immunization against hepatitis B |
ATE475668T1 (en) * | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | IMMUNIZATION BY VACCINATION OF DNA TRANSCRIPTION UNIT |
WO1995024929A2 (en) * | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US7732423B2 (en) * | 1994-04-27 | 2010-06-08 | Institut Pasteur | Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
WO1997005267A2 (en) * | 1995-07-26 | 1997-02-13 | Maxim Pharmaceuticals | Mucosal delivery of polynucleotides |
US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
WO1997017063A1 (en) * | 1995-11-09 | 1997-05-15 | Microbiological Research Authority | Microencapsulated dna for vaccination and gene therapy |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
US6723558B1 (en) | 1996-01-23 | 2004-04-20 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
WO1997028265A1 (en) * | 1996-02-05 | 1997-08-07 | University Of Massachusetts Medical Center | Measles immunization by dna transcription unit inoculation |
WO1998000554A1 (en) | 1996-07-03 | 1998-01-08 | Genetics Institute, Inc. | Protease fmh-1, an ice/ced-like protease |
FR2751228B1 (en) * | 1996-07-19 | 1998-11-20 | Rhone Merieux | BOVINE POLYNUCLEOTIDE VACCINE FOR INTRADERMAL ROUTE |
FR2751226B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES |
US6838552B1 (en) | 1997-08-14 | 2005-01-04 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
US6340463B1 (en) | 1996-08-14 | 2002-01-22 | Vanderbilt University | Identification of antigenic peptide sequences |
US6653128B2 (en) | 1996-10-17 | 2003-11-25 | University Of Florida | Nucleic acid vaccines against rickettsial diseases and methods of use |
US6025338A (en) * | 1996-10-17 | 2000-02-15 | University Of Florida | Nucleic acid vaccines against rickettsial diseases and methods of use |
US6593147B1 (en) | 1996-10-17 | 2003-07-15 | University Of Florida Research Foundation, Inc. | Nucleic acid vaccines against rickettsial diseases and methods of use |
US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US6200959B1 (en) | 1996-12-04 | 2001-03-13 | Powerject Vaccines Inc. | Genetic induction of anti-viral immune response and genetic vaccine for filovirus |
US7049428B1 (en) | 1998-03-04 | 2006-05-23 | Washington University | HCV variants |
US7338759B1 (en) | 1997-03-04 | 2008-03-04 | Washington University | HCV variants |
KR100220645B1 (en) * | 1997-07-04 | 1999-09-15 | 구광시 | Process for producing benzene derivatives |
US6020319A (en) * | 1997-07-24 | 2000-02-01 | New York Blood Center | Nucleic acid based immunotherapy of chronic hepatitis B infection |
US20030045492A1 (en) * | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
US20030125278A1 (en) * | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
EP1049712B1 (en) * | 1997-08-14 | 2007-01-24 | Institut Pasteur | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns |
US7923216B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
US7632980B1 (en) * | 1997-10-20 | 2009-12-15 | Gtc Biotherapeutics, Inc. | Modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems |
EP1060247B2 (en) | 1998-02-24 | 2011-10-26 | Sisters of Providence in Oregon | Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response |
GB9810236D0 (en) | 1998-05-13 | 1998-07-08 | Microbiological Res Authority | Improvements relating to encapsulation of bioactive agents |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6881723B1 (en) | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
US7022320B1 (en) | 1999-02-09 | 2006-04-04 | Powderject Vaccines, Inc. | Mycobacterium tuberculosis immunization |
WO2000061184A2 (en) * | 1999-04-08 | 2000-10-19 | Glenn Gregory M | Dry formulation for transcutaneous immunization |
US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US7078388B2 (en) * | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US20040002472A1 (en) * | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
AU1194802A (en) * | 2000-03-02 | 2001-12-11 | Univ Emory | DNA expression vectors and methods of use |
AU2002305052A1 (en) | 2001-03-13 | 2002-09-24 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
WO2002077263A2 (en) | 2001-03-22 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
NZ527971A (en) | 2001-03-27 | 2006-03-31 | Dendreon Corp | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
KR20040080940A (en) | 2001-05-14 | 2004-09-20 | 덴드레온 코포레이션 | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
US7816087B2 (en) | 2001-11-14 | 2010-10-19 | The United States Of America As Represented By The Department Of Health And Human Services | Gene expressed in prostate cancer and methods of use |
AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US7037506B2 (en) * | 2002-03-08 | 2006-05-02 | Schweltzer Chemical Corporation Ltd. | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry |
US7029681B2 (en) | 2002-03-08 | 2006-04-18 | Schweitzer Chemical Corporation | Multiple and multivalent DNA vaccines in ovo |
US6783759B2 (en) | 2002-03-27 | 2004-08-31 | Trustees Of The University Of Pennsylvania | Compositions and methods for modulating variola virus |
US6982156B2 (en) | 2002-03-27 | 2006-01-03 | Trustees Of The University Of Pennsylvania | Compositions and methods modulating variola and vaccinia virus |
AU2003278776A1 (en) * | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
JP2006516883A (en) | 2002-09-19 | 2006-07-13 | アメリカ合衆国 | P. Arashi polypeptide, Capsicum fly polypeptide, and method of use |
ATE429487T1 (en) | 2002-10-29 | 2009-05-15 | Us Gov Health & Human Serv | LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHOD OF USE |
JP2006508665A (en) * | 2002-12-04 | 2006-03-16 | アプライド モレキュラー エボリューション,インコーポレイテッド | A butyrylcholinesterase variant that alters the activity of chemotherapeutic agents |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
CN1898569A (en) | 2003-10-24 | 2007-01-17 | 伊缪因艾德有限公司 | Method of therapy |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
CA2568642A1 (en) | 2004-05-27 | 2005-12-15 | Centocor, Inc. | Cynomolgus prostate specific antigen |
US20060121031A1 (en) | 2004-12-07 | 2006-06-08 | Mckenzie Brent S | Relay vaccine |
US20070092449A1 (en) * | 2005-04-05 | 2007-04-26 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
EP2253957B1 (en) | 2006-03-14 | 2013-05-15 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis. |
US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
WO2008106551A2 (en) | 2007-02-28 | 2008-09-04 | The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. | Brachyury polypeptides and methods for use |
MX2009012924A (en) | 2007-06-08 | 2010-03-25 | Australian Poultry Crc Pty Ltd | Clostridial toxin netb. |
WO2009026660A1 (en) | 2007-08-30 | 2009-03-05 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
AU2010251880B2 (en) | 2009-05-27 | 2015-07-30 | Biotempus Pty Ltd | Methods of treating diseases |
AR078253A1 (en) | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY |
CN102713629B (en) | 2009-11-20 | 2016-02-24 | 俄勒冈健康科学大学 | For detecting the method for m tuberculosis infection |
WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US9597392B2 (en) | 2010-05-10 | 2017-03-21 | Ascend Biopharmaceuticals Pty Ltd. | Use of high molecular weight mannan for inducing and/or enhancing an immune response |
AR083533A1 (en) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | PROTEINS OF HEMAGLUTININ 5 (H5) FOR THE TREATMENT AND PREVENTION OF INFLECTIONS OF FLU |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
WO2012129295A1 (en) | 2011-03-21 | 2012-09-27 | Vaxin Inc. | Rapid and prolonged immunologic-therapeutic |
US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
PT2734544T (en) | 2011-07-18 | 2021-03-16 | Us Health | Methods and compositions for inhibiting polyomavirus-associated pathology |
AR088028A1 (en) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | PROTEINS H5, FROM H5N1 FOR MEDICINAL USE |
WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
WO2013039792A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogens based on an hiv-1 gp120 v1v2 epitope |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
CA2852709A1 (en) | 2011-10-28 | 2013-05-02 | Patrys Limited | Pat-lm1 epitopes and methods for using same |
US9133525B2 (en) | 2012-01-26 | 2015-09-15 | Luc Montagnier | Detection of DNA sequences as risk factors for HIV infection |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
US9775895B2 (en) | 2012-12-12 | 2017-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV therapeutics and methods of making and using same |
US9534041B2 (en) | 2013-02-12 | 2017-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that neutralize a norovirus |
ES2689878T3 (en) | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | H5 H5N1 flu virus proteins for use as a medicine |
EP2994163B1 (en) | 2013-05-09 | 2019-08-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10010606B2 (en) | 2013-09-30 | 2018-07-03 | Los Alamos National Security, Llc | Mosaic conserved region HIV immunogenic polypeptides |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
JP6502931B2 (en) | 2013-10-11 | 2019-04-17 | アメリカ合衆国 | TEM 8 antibody and use thereof |
GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
GB201319620D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
EP3079716B1 (en) | 2013-12-13 | 2019-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multi-epitope tarp peptide vaccine and uses thereof |
WO2015095770A1 (en) | 2013-12-20 | 2015-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic jc polyomavirus compositions and methods of use |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
US10398772B2 (en) | 2014-01-08 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy |
KR20160132494A (en) | 2014-04-03 | 2016-11-18 | 베링거잉겔하임베트메디카인코퍼레이티드 | Porcine epidemic diarrhea virus vaccine |
EP3160492A4 (en) | 2014-06-30 | 2018-01-03 | Murdoch Childrens Research Institute | Helicobacter therapeutic |
EP3473271B1 (en) | 2014-07-31 | 2022-07-20 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
EP3218397B8 (en) | 2014-11-14 | 2021-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2016090170A1 (en) | 2014-12-05 | 2016-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A potent anti-influenza a neuraminidase subtype n1 antibody |
EP3236998A1 (en) | 2014-12-24 | 2017-11-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Recombinant metapneumovirus f proteins and their use |
US10301377B2 (en) | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
ES2805206T3 (en) | 2015-03-10 | 2021-02-11 | Univ Massachusetts | GDF6 and BMP signaling approach for melanoma therapy |
LT3271389T (en) | 2015-03-20 | 2020-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to gp120 and their use |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
CN108135993B (en) | 2015-08-31 | 2022-03-22 | 贝林格尔·英格海姆维特梅迪卡有限公司 | Pestivirus vaccine for congenital tremor |
MX2018003173A (en) | 2015-09-16 | 2018-05-17 | Boehringer Ingelheim Vetmedica Inc | Salmonella choleraesuis-salmonella typhimurium vaccines. |
US10392441B2 (en) | 2015-10-07 | 2019-08-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
CA3003878A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017139392A1 (en) | 2016-02-08 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant hiv-1 envelope proteins and their use |
US10808011B2 (en) | 2016-03-09 | 2020-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant HIV-1 envelope proteins and their use |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
CA3015570A1 (en) | 2016-03-29 | 2017-10-05 | Peter Kwong | Substitutions-modified prefusion rsv f proteins and their use |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
TW201823467A (en) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | Canine adenovirus vectors |
EA201990711A1 (en) | 2016-09-20 | 2019-09-30 | Бёрингер Ингельхайм Ветмедика Гмбх | NEW EHV INSERT SITE ORF70 |
EP3516064A1 (en) | 2016-09-20 | 2019-07-31 | Boehringer Ingelheim Vetmedica GmbH | New promoters |
TW201823465A (en) | 2016-09-20 | 2018-07-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | New swine influenza vaccine |
WO2018057585A1 (en) | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
EP3518968B1 (en) | 2016-10-03 | 2022-01-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Hiv-1 env fusion peptide immunogens and their use |
WO2018071576A1 (en) | 2016-10-14 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of tumors by inhibition of cd300f |
US10960070B2 (en) | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
EP4234027A3 (en) | 2016-10-25 | 2023-12-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Prefusion piv f immunogens and their use |
WO2018081832A1 (en) | 2016-10-31 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide fragments from filoviruses and their uses |
RS64144B1 (en) | 2016-11-03 | 2023-05-31 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
MY191490A (en) | 2016-11-03 | 2022-06-28 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus |
EP3554538A2 (en) | 2016-12-16 | 2019-10-23 | Institute for Research in Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
CA3046684A1 (en) | 2017-01-30 | 2018-08-02 | Boehringer Ingelheim Animal Health USA Inc. | Porcine coronavirus vaccines |
EP3580235B1 (en) | 2017-02-10 | 2024-05-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US11235056B2 (en) | 2017-03-24 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Glycan-masked engineered outer domains of HIV-1 gp120 and their use |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
BR112020000711A2 (en) | 2017-07-12 | 2020-07-14 | Boehringer Ingelheim Animal Health USA Inc. | immunogenic compositions of senecavirus a and methods thereof |
EA202090628A1 (en) | 2017-09-23 | 2020-11-16 | Бёрингер Ингельхайм Ветмедика Гмбх | PARAMYXOVIRIDAE EXPRESSION SYSTEM |
EP3697440A1 (en) | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
US11905313B2 (en) | 2017-11-28 | 2024-02-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services. | Recombinant RSV G proteins and their use |
WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2019143934A1 (en) | 2018-01-19 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cancer activity of scbg3a2 and lps |
AU2019226034A1 (en) | 2018-02-21 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 Env and their use |
KR20200124713A (en) | 2018-02-23 | 2020-11-03 | 베링거잉겔하임베트메디카게엠베하 | Recombinant viral vector system expressing exogenous Pellan paramyxovirus gene and vaccine prepared therefrom |
JP7273840B2 (en) | 2018-03-19 | 2023-05-15 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | New EHV with inactivated UL18 and/or UL8 |
WO2019179966A1 (en) | 2018-03-19 | 2019-09-26 | Boehringer Ingelheim Vetmedica Gmbh | Ehv insertion site ul43 |
MX2020010018A (en) | 2018-03-26 | 2020-10-14 | Boehringer Ingelheim Animal Health Usa Inc | Method of producing an immunogenic composition. |
WO2020028902A1 (en) | 2018-08-03 | 2020-02-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nipah virus immunogens and their use |
WO2020058341A1 (en) | 2018-09-20 | 2020-03-26 | Boehringer Ingelheim Vetmedica Gmbh | Intranasal vector vaccine against porcine epidemic diarrhea |
JP7284822B2 (en) | 2018-09-20 | 2023-05-31 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Modified PEDV spike protein |
WO2020086483A1 (en) | 2018-10-22 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant gp120 protein with v1-loop deletion |
CA3120324A1 (en) | 2018-12-04 | 2020-06-11 | The Rockefeller University | Hiv vaccine immunogens |
EP3883609A2 (en) | 2018-12-20 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
WO2020227228A2 (en) | 2019-05-03 | 2020-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
EP3994173A1 (en) | 2019-07-02 | 2022-05-11 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Monoclonal antibodies that bind egfrviii and their use |
CN115515628A (en) | 2019-12-11 | 2022-12-23 | 美国政府(由卫生和人类服务部的部长所代表) | Mumps and measles virus immunogens and uses thereof |
CN115768784A (en) | 2020-02-06 | 2023-03-07 | 勃林格殷格翰动物保健有限公司 | Polypeptides for detecting anti-rhabdovirus antibodies |
CA3170322A1 (en) | 2020-02-11 | 2021-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
US20230348568A1 (en) | 2020-02-20 | 2023-11-02 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus monoclonal antibodies and uses thereof |
CN116096407A (en) | 2020-04-29 | 2023-05-09 | 美国政府(由卫生和人类服务部的部长所代表) | Recombinant human metapneumovirus F protein and application thereof |
WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
WO2022035860A2 (en) | 2020-08-10 | 2022-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Replication-competent adenovirus type 4-hiv env vaccines and their use |
US20220160866A1 (en) | 2020-10-05 | 2022-05-26 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
CN116438202A (en) | 2020-10-05 | 2023-07-14 | 勃林格殷格翰动物保健美国有限公司 | Fusion proteins comprising capsid proteins of the circoviridae family and chimeric virus-like particles comprising same |
WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
US20240115675A1 (en) | 2020-11-05 | 2024-04-11 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
CN117412769A (en) | 2021-01-15 | 2024-01-16 | 美国政府(由卫生和人类服务部的部长所代表) | Replication-competent adenovirus 4 SARS-COV-2 vaccine and its use |
IL304955A (en) | 2021-02-09 | 2023-10-01 | Us Health | Antibodies targeting the spike protein of coronaviruses |
CA3210753A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
AU2022230408A1 (en) | 2021-03-03 | 2023-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | La protien as a novel regulator of osteoclastogenesis |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
WO2022232648A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion-stabilized lassa virus glycoprotein complex and its use |
CA3216228A1 (en) | 2021-06-09 | 2022-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
CA3228275A1 (en) | 2021-08-03 | 2023-02-09 | Genoveffa Franchini | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
AU2022345251A1 (en) | 2021-09-17 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
WO2023086961A1 (en) | 2021-11-12 | 2023-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 spike fused to a hepatitis b surface antigen |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023192827A1 (en) | 2022-03-26 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to hiv-1 env and their use |
WO2023192835A1 (en) | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Base-covered hiv-1 envelope ectodomains and their use |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
US20240050555A1 (en) | 2022-04-05 | 2024-02-15 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition useful for vaccination against rotavirus |
WO2023220645A1 (en) | 2022-05-10 | 2023-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccine for human t-lymphotropic virus-1 |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4859465A (en) | 1984-04-20 | 1989-08-22 | The Regents Of The University Of California | Vaccine capable of eliciting multivalent antibodies |
WO1986000930A1 (en) * | 1984-07-20 | 1986-02-13 | Worcester Foundation For Experimental Biology | Retroviral vaccines and vectors and methods for their construction |
ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
IL76751A (en) * | 1984-11-01 | 1991-04-15 | American Home Prod | Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies |
US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4861864A (en) * | 1985-05-14 | 1989-08-29 | Albert Einstein College of Medicine of Yeshiva University (a Div. of Yeshiva University) | Rotavirus antigens |
US4631191A (en) * | 1985-06-20 | 1986-12-23 | Biotechnology Research Partners, Ltd. | Methods and compositions useful in preventing equine influenza |
US5186933A (en) | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
IL86354A0 (en) * | 1987-05-22 | 1988-11-15 | Orion Yhtymae Oy | Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof |
JP3055687B2 (en) * | 1987-08-10 | 2000-06-26 | ザ ユニバーシティー オブ メルボルン | Molecular cloning of human rotavirus serotype 4 gene 9 encoding VP7, neutralization of glycoprotein-specific major external capsids and expression of VP7 and fragments thereof for use in vaccines |
EP0398944A4 (en) * | 1988-02-05 | 1991-09-11 | Commonwealth Scientific And Industrial Research Organisation | Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence |
EP0748631B1 (en) * | 1988-09-13 | 2006-02-08 | Mérial | Viral vaccines |
WO1990002797A1 (en) * | 1988-09-15 | 1990-03-22 | North Carolina State University | Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
CA2489769A1 (en) * | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB9014951D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Equine herpesvirus-4 tk vaccine |
JPH06500232A (en) | 1990-08-15 | 1994-01-13 | サリオン・バイオロジクス・コーポレイシヨン | Self-assembling replication-defective hybrid virus particles |
US5298244A (en) | 1990-10-25 | 1994-03-29 | University Of Saskatchewan | Assembled viral particles and their use in a vaccine to rotaviral disease |
IE68404B1 (en) | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
US5337221A (en) | 1992-01-14 | 1994-08-09 | Musco Corporation | Means and method for highly controllable lighting |
US20060014714A1 (en) * | 1992-03-11 | 2006-01-19 | Robinson Harriet L | Genetic induction of anti-viral immune response and genetic vaccine for viruses |
ATE295895T1 (en) * | 1992-03-11 | 2005-06-15 | Powderject Vaccines Inc | GENETIC VACCINE AGAINST THE IMMUNO DEFICIENCY VIRUS |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5620896A (en) | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
WO1993025235A1 (en) | 1992-06-09 | 1993-12-23 | President And Fellows Of Harvard College | Aids therapeutics based on hiv-2 vpx peptides |
US5562909A (en) * | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
ATE475668T1 (en) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | IMMUNIZATION BY VACCINATION OF DNA TRANSCRIPTION UNIT |
FR2824846B1 (en) | 2001-05-16 | 2004-04-02 | Saint Gobain | SUBSTRATE WITH PHOTOCATALYTIC COATING |
CN101163714A (en) * | 2005-02-24 | 2008-04-16 | 马萨诸塞大学 | Influenza nucleic acids, polypeptides, and uses thereof |
-
1993
- 1993-01-27 US US08/009,833 patent/US5643578A/en not_active Expired - Lifetime
- 1993-03-17 WO PCT/US1993/002394 patent/WO1993019183A1/en active Application Filing
- 1993-03-17 CA CA002132836A patent/CA2132836C/en not_active Expired - Fee Related
- 1993-03-17 EP EP93907536A patent/EP0633937A1/en not_active Ceased
- 1993-03-17 JP JP5516675A patent/JPH07507203A/en active Pending
-
1994
- 1994-01-27 US US08/187,879 patent/US6841381B1/en not_active Expired - Lifetime
-
2003
- 2003-07-29 JP JP2003281600A patent/JP4362049B2/en active Active
-
2004
- 2004-01-22 US US10/763,049 patent/US7850956B2/en not_active Expired - Fee Related
-
2007
- 2007-06-06 JP JP2007150189A patent/JP4484904B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2132836A1 (en) | 1993-09-30 |
JP4484904B2 (en) | 2010-06-16 |
JPH07507203A (en) | 1995-08-10 |
US5643578A (en) | 1997-07-01 |
JP2007231025A (en) | 2007-09-13 |
JP4362049B2 (en) | 2009-11-11 |
US7850956B2 (en) | 2010-12-14 |
US6841381B1 (en) | 2005-01-11 |
WO1993019183A1 (en) | 1993-09-30 |
EP0633937A1 (en) | 1995-01-18 |
US20040208851A1 (en) | 2004-10-21 |
JP2004099603A (en) | 2004-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2132836C (en) | Immunization by inoculation of dna transcription unit | |
Robinson et al. | Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA | |
Taylor et al. | Protective immunity against avian influenza induced by a fowlpox virus recombinant | |
Kodihalli et al. | Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines | |
Fynan et al. | Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine | |
Fynan et al. | DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. | |
Kistner et al. | Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses | |
Macklin et al. | Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus | |
US5643577A (en) | Oral vaccine comprising antigen surface-associated with red blood cells | |
CA2181832C (en) | Immunization by inoculation of dna transcription unit | |
Brennan et al. | Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus | |
Tamura et al. | Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine | |
Mingxiao et al. | Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18 | |
JP2002531415A (en) | Peptide-based vaccine for influenza | |
US9505806B2 (en) | DNA vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the H5 haemagglutinin of an influenza virus and use of the DNA vaccine | |
Boyle et al. | Recombinant fowlpox virus vaccines for poultry | |
JP2009533477A (en) | Influenza virus vaccine | |
Cox et al. | Non‐lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication | |
Asanuma et al. | Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration | |
Heilman et al. | Influenza: status and prospects for its prevention, therapy, and control | |
Lucas et al. | Antibody production and protection against influenza virus in immunodeficient mice | |
Isaka et al. | Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice | |
Kammer et al. | Rabies vaccines: from the past to the 21st century | |
VASFI et al. | Efficacy of inactivated H9N2 avian influenza vaccine against non-highly pathogenic A/Chicken/Iran/ZMT-173/1999 infection | |
Lees et al. | Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |